Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
89.87(c) 89.08(c) 89.74(c) 90.68(c) 90.69(c) Last
11 314 643 8 661 887 8 652 543 5 978 972 8 089 029 Volume
+2.23% -0.88% +0.74% +1.05% +0.01% Change
More quotes
Financials (USD)
Sales 2019 17 124 M
EBIT 2019 9 859 M
Net income 2019 6 153 M
Debt 2019 8 347 M
Yield 2019 -
Sales 2020 19 276 M
EBIT 2020 11 277 M
Net income 2020 7 339 M
Debt 2020 3 455 M
Yield 2020 -
P/E ratio 2019 10,34
P/E ratio 2020 8,80
EV / Sales2019 4,19x
EV / Sales2020 3,47x
Capitalization 63 415 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
04/12Shareholder meeting
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/11CELGENE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
BU
02/05LYFEBULB : and Celgene Announce Call for Innovation Challenge Applications to Ad..
PR
02/04DEAL FILING : BMS added CVR late in Celgene negotiations
AQ
01/31CELGENE : Beats Profit Forecast As It Prepares For Takeover
DJ
01/31CELGENE : 4Q Earnings Snapshot
AQ
01/31CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
01/31CELGENE : Reports Fourth Quarter and Full Year 2018 Operating and Financial Resu..
BU
01/30Novartis 2019 growth outlook leaves investors wanting more
RE
01/30CELGENE : MaRS Innovations Triphase Accelerator Announces New Partnership with C..
AQ
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Sector news : Pharmaceuticals - NEC
02/15BRISTOL MYERS SQUIBB : Starboard gauges Bristol-Myers shareholder support for Ce..
RE
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -2-
DJ
02/15WSJ TAX GUIDE 2019 : What Investors Need to Know -- Journal Report
DJ
02/15WSJ TAX GUIDE 2019 : The Drug Industry -- Journal Report
DJ
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 98,4 $
Spread / Average Target 8,5%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION41.49%63 415
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536